Merck’s KEYTRUDA shows 38% reduction in death risk for renal cell carcinoma patients in Phase 3 KEYNOTE-564 trial

By on    Pharma Industry News  

Merck’s KEYTRUDA shows 38% reduction in death risk for renal cell carcinoma patients in Phase 3 KEYNOTE-564 trial

Merck & Co., Inc., a global healthcare leader, has recently unveiled groundbreaking results from its Phase 3 KEYNOTE-564 trial. This pivotal study demonstrates that KEYTRUDA, Merck’s innovative anti-PD-1 therapy, significantly reduces the risk of death by 38% compared to placebo, marking a milestone in adjuvant therapy for patients with renal cell carcinoma (RCC) post-nephrectomy. Presented […]

Merck’s WELIREG meets primary endpoint of PFS in Phase 3 RCC trial

By on    Pharma Industry News  

Merck’s WELIREG meets primary endpoint of PFS in Phase 3 RCC trial

Global pharmaceutical leader Merck has announced that WELIREG (belzutifan), its pioneering oral HIF-2α inhibitor, has achieved a critical milestone in its Phase 3 trial LITESPARK-005. The trial, conducted on adult patients with advanced renal cell carcinoma (RCC) that progressed following PD-1/L1 checkpoint inhibitor and VEGF-TKI therapies, met its primary endpoint by demonstrating a statistically significant […]